Role of resveratrol supplementation in regulation of glucose hemostasis, inflammation and oxidative stress in patients with diabetes mellitus type 2: A randomized, placebo-controlled trial.

Study answer

What this study found

Resveratrol improved glycemic control and insulin resistance versus placebo over 24 weeks, while also reducing inflammatory and oxidative stress markers and favorably modulating circulating microRNAs. Compared with placebo, FPG fell by -0.50 (95% CI -0.94 to -0.06; p = 0.016), HbA1c by -0.45 (-0.88 to -0.02; p = 0.033), insulin by -1.31 (-2.24 to -0.38; p = 0.001), and HOMA-IR by -0.83 (-1.37 to -0.29; p = 0.001). hs-CRP (-0.35), IL-6 (-1.99), TNF-α (-1.25), MDA (-0.36), and microalbuminuria (-0.67) also improved, whereas lipid outcomes did not change significantly. miRNA-34a-5p,…

Study & population

Randomized, double-blind, placebo-controlled parallel-group trial in adults with type 2 diabetes aged 18-70 years who had been using oral hypoglycemic agents for at least 1 year, with HbA1c 7-12% and BMI at or below 35 kg/m2.

Intervention

Resveratrol 200 mg was taken orally once daily as a capsule with breakfast for 24 weeks, added to ongoing oral hypoglycemic therapy.

Key limitation

The trial was relatively small in the active arm and lasted only 24 weeks, which limits confidence in durability and generalizability.

View full study detailsView sourceOpen PDF

Original abstract